Rebates, discounts drove Janssen's average net price down 4.6% in 2017 even as average list price increased 8.1%; transparency report emphasizes value-based contracts for prostate cancer, diabetes drugs.
Janssen Pharmaceutical Cos.'s average net price increase for 2017 reflects the demands of payers and providers for greater discounts and rebates. The company reported that while its average list price (wholesale acquisition cost) increased 8.1% – pretty much the same as the previous year – the average net price (wholesale acquisition cost minus rebates, discount and returns) declined 4.6%.
Janssen disclosed the pricing information in its second annual
The first two classes of negotiated drugs under the Inflation Reduction Act would not benefit from a rare disease adjustment House Republicans included in their reconciliation package.
US trade and tariff leverage might successfully push European and other countries to pay more for medicines, but if not, President Trump’s executive order includes potential US drug withdrawal and other options to entice industry to lower US prices.
Decision in AstraZeneca’s lawsuit against the Health and Human Services Department is a precedent-setting victory for the government and a blow to manufacturer efforts to block the price negotiation program.
President Trump's ongoing interest in the policy, which would ensure the US government pays no more for prescription drugs than the lowest price available in comparable countries, continues to gain attention.
Brazil’s drug pricing authorities are planning to introduce, among other things, a new drug category for biosimilars to ensure the pricing procedures for such medicines are reflected in the official pricing framework.
Brazil plans to clarify its medicine pricing framework, for example by outlining the procedures for setting medicine prices and bring it up to date with recent developments in the sector.
England’s health technology assessment institute explains how its sandbox environment is helping to test new evaluation methods for drugs or indications with which it does not have experience, such as metabolic dysfunction-associated steatohepatitis.
